Clinical trial
A Single-arm Phase-I Trial for the Determination of Safety and Feasibility of the Intravenous Administration of Mitomycin C-treated Donor Peripheral Blood Mononuclear Cells (MICs) for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients (TOL-1 Study)
NCT02560220 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm Phase-I Trial for the Determination of Safety and Feasibility of the Intravenous Administration of Mitomycin C-treated Donor Peripheral Blood Mononuclear Cells (MICs) for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients (TOL-1 Study)
- Lead sponsor
- Heidelberg University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 5, 2015
- Completion date
- April 18, 2017
- Enrollment
- 14 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.